Loading
Latest filing published 07 Jul 2025 for Ernexa Therapeutics Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Sandra M. Gurrola, listed as chief executive, appears in our data through filings on Ernexa Therapeutics Inc. shares, published by SEC (Form 4). Between 21 June 2022 and 21 June 2025, the trades on record add up to 4 filings.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
The newest entry dates from 7 July 2025: an option exercise, in Ernexa Therapeutics Inc. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations